Andrew LaFrence
Analyst · Marion Road Capital Management
Thank you, Jay. In the next few minutes, I'll provide certain details of our financial performance in the first quarter of 2024, but I would encourage you to review our press release issued earlier this morning and our latest filings this week with the U.S. Securities and Exchange Commission as they contain far more information about our business operations and financial results then we will cover on this call. As a continued theme, we have historically noted that our individual quarterly performance can be affected by outside factors. These might include timing fluctuations, including seasonal fluctuations, customer shipments and supply chain issues. Any of these could materially impact a particular quarter either positively or negatively.
Consequently, we believe it is more appropriate to review our business on a 12-month basis rather than focusing on quarterly performance. This approach will help normalize these potential anomalies and offer a better gauge of our strategy's long-term success. So today, while I'll focus most of my comments on the first quarter results, I will provide some comparisons for the 12-month period ending March 31, 2024, and compared with the same period ended March 31, 2023.
As of March 31, 2024, we did see sustained year-over-year 90-day backlogs. And for the quarter, we realized gross margin improvement as well as increased levels of net income, EBITDA as compared with the first quarter of 2023. Net sales for Q1 2024 totaled $34.2 million. This represents a 1.9% decrease from net sales of $34.9 million in the first quarter of 2023. Nortech's first quarter net sales performance was driven by year-over-year growth in the aerospace and defense category, offset by decreases in medical and industrial. For the quarter, the medical market was down by $1.1 million or 5.1% as compared with the same quarter in 2023, with the majority of the decrease coming from medical component products. For the quarter, net sales from the aerospace and defense category totaled $5.9 million, a 44.9% increase from the prior year quarter. And net sales from Nortech's industrial category were down $8.1 million or 14.8% from the prior year quarter.
First quarter 2024 gross margin totaled $5.4 million or 15.9% of net sales compared with gross profit of $5.5 million or 15.7% of net sales in the same prior year quarter. First quarter operating expenses totaled $4.3 million, a 3.1% decrease from the first quarter 2023 operating expenses of $4.4 million. As a result of our performance in the first quarter of 2024, we realized net income of $765,000 or $0.26 per diluted share compared with $681,000 or $0.23 per diluted share in the same quarter of 2023.
As Jay discussed in his comments, our Board of Directors just today approved 2 actions to facilitate our optimization of our North American facilities footprint. First, we announced the closure of our Blue Earth facility by the end of 2024. The decision to close our Blue Earth facility was not without much forethought and deliberation. While we're closing this facility, our commitment to all of our Blue Earth employees will continue through offering of employment at another Nortech facility in Minnesota. We hope that all of our Blue Earth employees will continue with Nortech.
We estimate the Blue Earth closing will result in a restructuring charge of $1 million to $1.1 million in the last 3 quarters of 2024. These expenses include estimated noncash impairment charges of $400,000 with the remaining costs consisting of payments to move equipment, shut down the Blue Earth facility and employee retention. We expect to pay substantially all of the cash restructuring costs in 2024.
Second, we have signed an amendment to our Maple Grove, Minnesota, lease to reduce our square footage by approximately 30%, while repositioning the remaining retained space to better serve our needs for the next several years. We expect to realize annual savings starting in 2025 of at least $1.6 million related to these 2 consolidation activities.
Moving to the cash flow statement. First, for the quarter ended March 31, 2024, net cash provided by operating activities totaled $2.8 million as compared with $1.7 million for the same period in 2023. As noted in our press release distributed this morning, we used earnings before interest, tax, depreciation, amortization or EBITDA as a key performance indicator to manage our business. In the press release, we have provided a reconciliation of our financial performance determined in accordance with the U.S. generally accepted accounting principles and EBITDA. For the quarter ended March 31, 2024, EBITDA increased 5.1% to $1.637 million as compared to $1.558 million for the same period in 2023. This increase is largely due to improved gross margins and operating expense management.
Turning to the balance sheet. As of March 31, 2024, cash and cash equivalents totaled $4 million, up from $1.7 million as of December 31, 2023. The fluctuation in cash balances reflects timing of cash receipts and expenditures as well as line of credit borrowings. We extended -- excuse me, we ended the first quarter of 2024 with [ $8.1 ] million of borrowing capacity under our line of credit.
Accounts receivable as of March 31, 2024, were $16.1 million, down from $19.3 million as of December 31, 2023. This is in line with our strong fourth quarter sales and the expected timing of customer payments. Inventories were $23 million as of March 31, 2024, as compared with $21.7 million as of December 31, 2023.
Our contract asset, which represents revenue earned but not yet billed to customers decreased slightly to $14.2 million as of March 31, 2024, as compared with $14.5 million at the end of '23. This decrease reflects the timing of customer shipments. As a reminder, the majority of our net sales are generated from products manufactured specifically to a customer's unique application. And as such, we recognize revenue in accordance with U.S. generally accepted accounting principles as we produce those products.
As we also disclosed in our press release issued earlier today, we have presented non-GAAP results including trailing 12 months financial data in EBITDA. For the trailing 12-month period ended March 31, 2024, net sales were $138.7 million as compared with $138.3 million for the same 12-month period ended March 31, 2023. In addition, EBITDA for the 12-month period ended March 31, 2024, was $8.1 million as compared with $6.7 million for the 12-month period ended March 31, 2023.
As we stated in March, our top financial priorities for 2024 remain unchanged. First, we are extremely focused on continuing to strengthen our balance sheet. Next, we will take further advantage of opportunities to align our operations and infrastructure with the market demand that we are seeing to deliver sustainable EBITDA growth as well as driving improvements in free cash flow. Coupled with disciplined lean operation execution, expense management and R&D innovation, we believe Nortech can deliver on our objectives.
With that, I will turn it back over to Jay for his closing comments. Jay?